LLY News

Latest breaking news and updates for LLY stock.

Track all markets on TradingView

Lanier Law Firm Representing Health Choice Alliance in Litigation Alleging Eli Lilly Offered Kickbacks to Texas Health Care Providers

MARSHALL, Texas--(BUSINESS WIRE)--Texas Attorney General Ken Paxton has filed a lawsuit in state court against Eli Lilly and Co., accusing the pharmaceutical giant of bribing and inducing medical p...

How might the outcome of this case influence the valuation of Eli Lilly’s stock relative to the broader pharmaceutical index? Is there a risk of a material adverse clause being triggered in any of Eli Lilly’s existing debt agreements or credit facilities? Could the lawsuit affect the pricing or market access for the specific high‑margin drugs mentioned in the allegations?
Lawsuits
9 days ago
Read more businesswire

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity

Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as well as additional development and commercial milestones, ...

What are the broader implications for the biotech sector's valuation given the growing focus on small‑molecule GPCR therapeutics for obesity? How might this deal affect analyst ratings and price targets for Eli Lilly and Superluminal Medicines? What are the risks if the joint development program fails to meet pre‑clinical or clinical endpoints?
Partnership
9 days ago
Read more prnewswire

Elevating Patient Care: Senderra Specialty Pharmacy Adds EBGLYSS™ (lebrikizumab-lbkz), Lilly's First-Line Biologic Treatment for Moderate-to-Severe Atopic Dermatitis, to SenderraCare+ for a Streamlined, Empowering Digital Patient Experience

SenderraCare+ redefines specialty therapy by consolidating enrollment, adherence support, and medication management into one intuitive, in real-time digital platform. It accelerates treatment initi...

Will the launch have any material impact on Eli Lilly’s stock price in the short term (e.g., in the next 1‑3 months) and in the longer term (6‑12 months)? What are the potential risks or downsides (e.g., adoption challenges, integration issues) that could impact the expected benefits of the digital platform? How does the launch align with Eli Lilly’s broader pipeline and strategic focus on specialty medicines?
Product launch
15 days ago
Read more prnewswire

Lilly reports second-quarter 2025 financial results and raises guidance

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1.5 billion to be in the ran...

How does the guidance upgrade affect the relative position of LLY within the biotech/ pharma sector index? What regulatory, pricing, or payer risk factors could threaten the projected growth of Zepbond and Mounjaro? How will the Q2 results affect short‑term technical levels and trader sentiment (e.g., momentum, short‑interest) for LLY stock?
Earnings
16 days ago
Read more prnewswire

Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity

In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies at 72 weeks Orforglipron achieved...

How sensitive is the stock to any upcoming data releases or updates from the ATTAIN‑2 trial? What potential partnership or licensing opportunities could arise from this oral GLP‑1 platform? Could the oral formulation create a competitive advantage in patient adherence versus injectables?
Clinical trials
16 days ago
Read more prnewswire